mepolizumab (Q3306175)

DrugBank

parenteral route of administration

17 November 2015

3.6 milligram

route of administration

1 reference

reference URL

https://www.whocc.no/atc_ddd_index/?code=R03DX09

active ingredient in

Nucala

1 reference

European Medicines Agency product number

EMEA/H/C/003860

reference URL

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003860/human_med_001933.jsp

World Health Organisation international non-proprietary name

22 March 2017

mepolizumab (English)

1 reference

Mepolizumab (English)

medical condition treated

19 January 2016

Churg-Strauss syndrome

1 reference

Drug Indications Extracted from FAERS

LiverTox likelihood score

2 October 2018

LiverTox toxicity likelihood category E

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Mepolizumab

11 April 2016

1 reference

Mepolizumab (English)

DrugBank

17 November 2015

1 reference

Mepolizumab (English)

publication date

17 November 2015

Identifiers

2 references

Mepolizumab (English)

publication date

17 November 2015

Global Substance Registration System

14 February 2018

1 reference

Mepolizumab (English)

19 January 2016

0 references

1 reference

Guide to Pharmacology Ligand ID

Mepolizumab (English)

publication date

17 November 2015

R03DX09

0 references

0 references

mepolizumab

0 references

RxNorm ID

1720597

1 reference

Global Substance Registration System

14 February 2018

0 references

1 reference

Global Substance Registration System

UNII

90Z2UF0E52

MedlinePlus drug identifier

14 February 2018

a615058

0 references

PatientsLikeMe treatment ID

0 references

1 reference

26 February 2018

1 reference

Mepolizumab (English)